Higher FSH Level Is Associated With Increased Risk Of Incident Hip Fracture In Older Adults, Independent Of Sex Hormones.

FSH aging fracture risk osteoporosis

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
12 Oct 2024
Historique:
received: 14 05 2024
revised: 17 09 2024
accepted: 11 10 2024
medline: 12 10 2024
pubmed: 12 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

Higher levels of FSH are associated with bone loss among women during the perimenopausal transition and among older men, independent of estradiol and testosterone levels, but whether higher FSH is an independent fracture risk factor is unknown. Determine whether baseline FSH level predicts subsequent hip fracture in older adults. Using a case-cohort design, we randomly sampled 295 participants stratified by sex from the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort, including 25 participants with incident hip fracture within 10 years after baseline. We sampled an additional 230 sex-stratified participants with incident hip fracture. Serum FSH and sex hormone levels were measured at baseline. Robust weighted Cox proportional hazards models were used to determine the relationship between FSH and hip fracture risk. Incident hip fracture. As no interaction was identified between FSH and sex for the relationship with fracture, men and women were pooled for analysis. Higher levels of FSH were associated with a significantly increased risk of incident hip fracture in models adjusted for age and sex [hazard ratio (HR) 1.24 (95% CI 1.04-1.48, p=0.02)] and after further adjustment for estradiol, testosterone, and sex hormone binding globulin levels [HR 1.20 (95% CI 1.01-1.44, p=0.04) per sex-specific SD increase in FSH level]. Higher FSH is associated with increased risk of subsequent hip fracture. Our findings support a growing body of evidence for direct pleiotropic effects of FSH on bone, and for a role for FSH in aging and disability independent of sex hormone levels.

Identifiants

pubmed: 39394788
pii: 7819205
doi: 10.1210/clinem/dgae690
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Published by Oxford University Press on behalf of the Endocrine Society 2024.

Auteurs

Eileen H Koh (EH)

Department of Medicine, University of Washington, Seattle, WA, USA.

Susan K Ewing (SK)

Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.

Sigurdur Sigurdsson (S)

Icelandic Heart Association Research Institute, Kopavogur, Iceland.

Vilmundur Gudnason (V)

Icelandic Heart Association Research Institute, Kopavogur, Iceland.
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Trisha F Hue (TF)

Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.

Eric Vittinghoff (E)

Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.

Claes Ohlsson (C)

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, Sweden.

Åsa Tivesten (Å)

Wallenberg Laboratory for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden.
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Louise Grahnemo (L)

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, Sweden.

Tony Yuen (T)

Center for Translational Medicine and Pharmacology and Mount Sinai Bone Program, and Departments of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.

Mone Zaidi (M)

Center for Translational Medicine and Pharmacology and Mount Sinai Bone Program, and Departments of Medicine and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.

Clifford J Rosen (CJ)

MaineHealth Institute for Research, Scarborough, ME, USA.

Ann V Schwartz (AV)

Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.

Anne L Schafer (AL)

Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Department of Medicine, University of California, San Francisco, CA, USA.
Endocrine Unit, San Francisco VA Health Care System, San Francisco, CA, USA.

Classifications MeSH